320 related articles for article (PubMed ID: 36032113)
1. Using the canine microbiome to bridge translation of cancer immunotherapy from pre-clinical murine models to human clinical trials.
Kleber KT; Iranpur KR; Perry LM; Cruz SM; Razmara AM; Culp WTN; Kent MS; Eisen JA; Rebhun RB; Canter RJ
Front Immunol; 2022; 13():983344. PubMed ID: 36032113
[TBL] [Abstract][Full Text] [Related]
2. Comparative Immunology and Immunotherapy of Canine Osteosarcoma.
Mason NJ
Adv Exp Med Biol; 2020; 1258():199-221. PubMed ID: 32767244
[TBL] [Abstract][Full Text] [Related]
3. Complex interactions between the microbiome and cancer immune therapy.
Schwartz DJ; Rebeck ON; Dantas G
Crit Rev Clin Lab Sci; 2019 Dec; 56(8):567-585. PubMed ID: 31526274
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
Ren S; Feng L; Liu H; Mao Y; Yu Z
Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
[TBL] [Abstract][Full Text] [Related]
5. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
6. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
7. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
Huang J; Jiang Z; Wang Y; Fan X; Cai J; Yao X; Liu L; Huang J; He J; Xie C; Wu Q; Cao Y; Leung EL
Curr Opin Pharmacol; 2020 Oct; 54():1-10. PubMed ID: 32619934
[TBL] [Abstract][Full Text] [Related]
8. Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans.
Oh W; Kim AMJ; Dhawan D; Kirkham PM; Ostafe R; Franco J; Aryal UK; Carnahan RH; Patsekin V; Robinson JP; Knapp DW; Lim SO
Cancer Res Commun; 2023 May; 3(5):860-873. PubMed ID: 37377896
[TBL] [Abstract][Full Text] [Related]
9. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.
Matson V; Chervin CS; Gajewski TF
Gastroenterology; 2021 Jan; 160(2):600-613. PubMed ID: 33253684
[TBL] [Abstract][Full Text] [Related]
10. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
[TBL] [Abstract][Full Text] [Related]
11. Gut Microbiota in Cancer Immune Response and Immunotherapy.
Zhou CB; Zhou YL; Fang JY
Trends Cancer; 2021 Jul; 7(7):647-660. PubMed ID: 33674230
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.
Lu Y; Yuan X; Wang M; He Z; Li H; Wang J; Li Q
J Hematol Oncol; 2022 Apr; 15(1):47. PubMed ID: 35488243
[TBL] [Abstract][Full Text] [Related]
13. The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy.
Sevcikova A; Izoldova N; Stevurkova V; Kasperova B; Chovanec M; Ciernikova S; Mego M
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008915
[TBL] [Abstract][Full Text] [Related]
14. Exploring the emerging role of the microbiome in cancer immunotherapy.
Fessler J; Matson V; Gajewski TF
J Immunother Cancer; 2019 Apr; 7(1):108. PubMed ID: 30995949
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials.
Park R; Umar S; Kasi A
Curr Colorectal Cancer Rep; 2020 Aug; 16(4):81-88. PubMed ID: 32607098
[TBL] [Abstract][Full Text] [Related]
16. Gut Microbiome Modulation Via Fecal Microbiota Transplant to Augment Immunotherapy in Patients with Melanoma or Other Cancers.
McQuade JL; Ologun GO; Arora R; Wargo JA
Curr Oncol Rep; 2020 Jun; 22(7):74. PubMed ID: 32577835
[TBL] [Abstract][Full Text] [Related]
17. Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy.
Yi M; Jiao D; Qin S; Chu Q; Li A; Wu K
Integr Cancer Ther; 2019; 18():1534735419876351. PubMed ID: 31517538
[TBL] [Abstract][Full Text] [Related]
18. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target.
Zhang M; Liu J; Xia Q
Exp Hematol Oncol; 2023 Sep; 12(1):84. PubMed ID: 37770953
[TBL] [Abstract][Full Text] [Related]
19. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
Park JS; Gazzaniga FS; Wu M; Luthens AK; Gillis J; Zheng W; LaFleur MW; Johnson SB; Morad G; Park EM; Zhou Y; Watowich SS; Wargo JA; Freeman GJ; Kasper DL; Sharpe AH
Nature; 2023 May; 617(7960):377-385. PubMed ID: 37138075
[TBL] [Abstract][Full Text] [Related]
20. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
